Innovative Cirrhosis Stages Prediction

Ezhil Nandhini Karthikeyan
School of Computing
Dublin City University
Dublin, Ireland

Sudharsan Swaminathan
School of Computing
Dublin City University
Dublin, Ireland

***Abstract*—Liver diseases pose a significant global health burden, underscoring the critical need for early detection and effective management strategies. In response, this project introduces an Integrated Liver Disease Management Platform that leverages cutting-edge predictive modeling and a Clinical Decision Support System (CDSS) to revolutionize liver healthcare delivery. By amalgamating advanced machine learning techniques with real-time risk assessment capabilities, our platform aims to provide healthcare professionals with precise insights and personalized care plans tailored to individual patient needs. Emphasizing ethical considerations, we adhere rigorously to the regulations outlined by the European Health Organisation and the Health Insurance Portability and Accountability Act (HIPAA), particularly concerning Electronic Health Records (EHR). This endeavor signifies a significant step towards enhancing the diagnosis, treatment, and overall management of liver diseases, ultimately improving patient outcomes and healthcare efficiency.**

I. Introduction

Liver diseases affect millions worldwide, and early detection is key. This project is set to provide a narrative by introducing an Integrated Liver Disease Management Platform. This platform will bring together cutting-edge predictive modeling and a Clinical Decision Support System (CDSS) [2] to transform how we approach liver health.

Why It Matters: Liver diseases cover a spectrum of conditions, from fatty liver disease [1] to more severe cases like cirrhosis and hepatocellular carcinoma. Timely identification of risks and personalized care plans can make all the difference. Our goal is to use advanced machine learning models to provide healthcare professionals with precise [3][4], real-time risk assessments [6][7] and support through the CDSS during consultations [1].

Our Ethical Aims: Taking that this is related to EHR(Electronic Health Records) we strictly abide by the rules and regulations provided by the European Health Organisation and also The Health Insurance Portability and Accountability Act (HIPAA).

2. Literature Survey

2.1 This Paper states that the patients who have NAFLD (Non-alcoholic fatty liver disease) have a care gap missing to calculate the annual laboratory testing which is performed to calculate the FIB4(Fibrosis) score.The authors have addressed this gap by either referring to Elastography-Based Testing or Considering the Biochemical and clinical characteristics in a hepatology clinic.The authors were able to conclude that less than 3% of patients who are diagnosed with abnormal FIB-4 go for further treatment or evaluation and also 52% of patients with NAFLD do not undergo annual tests within primary care settings.

2.2 The authors developed a CDSS(Clinical Decision Support System) that performs independently. While performing this process they found consistent data that was laboratory focused. They have referred to the ALFIE Study which states that 21.7 % of the asymptomatic population from Scotland had at least one Abnormal Liver Function Test (ALFT).Due to some limitations which arise when using Case-Based Reasoning, Artificial Neural Networks, and Hybrid Approaches even after providing good results Multiple DSS techniques were used to overcome this.The DSS developed in this case consisted of 3 sections: Expert System Algorithm, DILI (Drug Induced Liver Injury) assessment tool, and Interactive UI guide for clinicians.When testing this DSS, The Authors were able to get 18 out of 20 case results the algorithm was able to find the precise cause of the ALFT, and also it helped the clinicians move forward in the right path of treatments.

2.3 The Authors have developed a hypothesis that consists of evolutionary intelligence methods that can be modeled corresponding to positive and negative rules. These can be used for clinical decision support by providing efficient results and diagnosis.The authors have used a MOPNAR method. This method is a multi-objective rule miner from fibrosis without the interference of a clinical technician.The results from the MOPNAR method consist of 4 sections.The first section is represented by [-1,0,1].if this section's attribute has a value of -1 this section is ignored in the association rule.The second section consists of interval and it is interpreted in 0's and 1's. The third and fourth section is used for lower and upper-bound attributes.The results of the MOPNAR method are also compared with the results of another association rule mining method using a genetic algorithm named MOEA-GHOSH. While performing the result comparison of these 2 methods the MOPNAR proved to be more efficient than the MOEA-GHOSH method.

2.4 The study offers a thorough analysis of nonalcoholic fatty liver disease (NAFLD) and the most recent revisions to

guidelines from the perspectives of the US, Asia, and Europe. The authors address the increasing incidence of non-alcoholic fatty liver disease (NAFLD) and its relationship to obesity and metabolic syndrome, emphasizing the need for a successful strategy for diagnosis, treatment, and prevention. It goes over important topics like what constitutes substantial alcohol use, screening standards, and fibrosis assessment techniques. The paper's comprehensive nature is enhanced by the incorporation of pharmacological interventions and the focus on early recognition and intervention. The review also discusses how NAFLD is changing, with a focus on the transition to metabolic-associated fatty liver disease (MAFLD) and its possible effects on diagnosis and treatment approaches. The authors rightly emphasize the significance of hepatocellular carcinoma monitoring and take into account the requirement for future guidelines to adjust to discoveries in the field.Overall, the paper offers a fair and impartial analysis of non-alcoholic fatty liver disease (NAFLD), highlighting significant results and incorporating the most recent guidelines updates.

2.5 The authors have provided the advantages of EASL CPGs as it is widely distributed and also a small suggested upgrade by including a simple delphine process which helps in approaching a much broader audience and involves Academic experts and stakeholders rather than having only the board of directors for CPG and EASL board.This led to making precise decisions since the process is an iterative approach to getting results in similar individuals having relevant issues.They follow PICO.The authors suggest that this approach is reasonable, accurate, and transparent.

2.6 In this paper the authors have used a general methodology following PICO which is patient or problems, Interventions, Comparison of methods, and Outcomes. they have segregated the problem into several common liver diseases and added a bunch of statements with the judgments in four categories.Strong consensus, consensus, majority agreement, no consensus. The statements were formed based on the guidelines provided by the ESPEN and German S3 guidelines.Each liver diseases have its respective statements that were validated based on several articles and they were able to find 957 articles which was then filtered down by removing duplicates and similar papers. The list was narrowed down to 122 articles.

2.7 In this the author develops a nutritional chart for people suffering from cirrhosis by assessing their nutritional status using a simple mathematical formula:

BMI ± Hand grip Strength

The patients who are affected by cirrhosis are required to take 4-7 meals a day and also if they have ascites or edema it is suggested to take a low sodium diet.The study based on this led to a discovery that cirrhotic patients have high protein intake to achieve a balanced nitrogen metabolism.

2.8 The authors in this article have compared the outcomes of the AlbuminBilirubin score(ALBI) with the Model for End-Stage Liver (MELD) in the prediction of post-hepatectomy liver failure and mortality.The predictive accuracy is obtained by checking the ROC-AUC score.The data used consisted of 13783 patient records and scores are found as respectively: AUC 0.67 vs AUC 0.60 for ALBI and MELD. for mortality, the scores are as follows AUC 0.70 vs AUC 0.58.So the comparative studies suggest that ALBI scores are better compared to MELD scores.

2.9 The paper from PubMed Central explores the use of non-invasive serum markers in diagnosing liver fibrosis, which aligns closely with your project's aim of leveraging advanced predictive modeling for early detection of liver diseases. It discusses the potential of these markers in stratifying patients based on disease severity, offering insights into personalized care plans, a key component of your Integrated Liver Disease Management Platform.

The paper "Machine Learning in Liver Disease: Ready for Prime Time?" provides a comprehensive overview of the current state of machine learning applications in liver disease diagnosis and management. It delves into the potential of machine learning algorithms in predicting disease progression, identifying treatment responses, and enhancing clinical decision-making. The review critically examines the strengths and limitations of existing studies, highlighting the need for standardized data collection and validation methods to ensure the reliability and generalizability of machine learning models in liver disease. Overall, this paper serves as a valuable resource for researchers and clinicians seeking to leverage machine-learning techniques to improve patient care in hepatology.

2.10 The study published in Hepatology introduces a novel non-invasive diagnostic tool for liver fibrosis, showcasing advancements in liver disease diagnosis. This paper provides valuable insights into the latest technologies and methodologies used in liver disease diagnosis, which can inform the development of your predictive modeling approach and enhance the precision of risk assessments within your platform.

"Machine learning in liver transplantation: A systematic review" presents a thorough analysis of machine learning approaches employed in liver transplantation research. The review discusses the diverse applications of machine learning, ranging from predicting post-transplant outcomes to optimizing donor-recipient matching. It critically evaluates the strengths and weaknesses of existing studies, emphasizing the potential of machine learning to enhance decision-making processes in liver transplantation. Furthermore, the paper identifies areas for future research, such as integrating clinical and genomic data to improve predictive accuracy. Overall, this review contributes valuable insights to the growing body of literature on machine learning in liver transplantation, highlighting its role in advancing patient care and transplant outcomes.

2.11 In the paper from ScienceDirect, the authors propose a machine learning-based predictive model for the prognosis of liver cirrhosis. This aligns with your project's objective of incorporating cutting-edge predictive modeling techniques to provide real-time risk assessments. The study's findings on

predicting disease progression could enhance the functionality of your platform in monitoring and managing liver diseases.

"Machine learning for the prediction of survival outcomes in patients with cirrhosis: A systematic review and meta-analysis" offers a comprehensive synthesis of studies utilizing machine learning for predicting survival outcomes in patients with cirrhosis. The review examines the predictive performance of various machine learning algorithms and identifies key predictors associated with survival. It also discusses methodological considerations and potential biases in the included studies, underscoring the importance of standardized reporting guidelines and validation techniques. Overall, this paper provides valuable insights into the current landscape of machine learning applications in predicting survival outcomes in cirrhotic patients, informing future research directions and clinical practice in hepatology.

Predicting survival in patients with end-stage liver disease: An update" offers a comprehensive review of prognostic models used to predict survival in patients with end-stage liver disease (ESLD). It discusses the evolution of prognostic scoring systems, such as the Model for End-Stage Liver Disease (MELD) and Child-Turcotte-Pugh (CTP) score, and evaluates their accuracy and clinical utility. Moreover, it explores novel prognostic markers and emerging technologies for predicting survival in ESLD patients. This review provides valuable insights for clinicians involved in the management of patients with advanced liver disease, aiding in treatment decision-making and resource allocation.

2.12 The paper in Alimentary Pharmacology & Therapeutics explores the role of genetic factors in the progression of non-alcoholic fatty liver disease (NAFLD), offering insights into personalized risk assessment and management strategies. Integrating such genetic markers into your predictive modeling approach could enhance the platform's ability to tailor care plans to individual patient needs and improve overall efficacy in managing NAFLD.

"Machine learning for the prediction of variceal bleeding in patients diagnosed with compensated cirrhosis" presents a systematic review and meta-analysis of machine learning models for predicting variceal bleeding in patients with compensated cirrhosis. The review evaluates the performance of different machine learning algorithms and identifies predictive factors associated with variceal bleeding risk. It discusses the implications of machine learning in risk stratification and clinical decision-making, emphasizing the potential to improve patient outcomes through early intervention and personalized management strategies. Overall, this paper contributes valuable insights into the utility of machine learning in predicting variceal bleeding risk, highlighting its role in enhancing patient care and reducing morbidity in cirrhotic patients.

2.13 Application of artificial intelligence and machine learning in liver disease diagnosis and prognosis" provides a comprehensive overview of the current state of artificial intelligence and machine learning applications in liver disease diagnosis and prognosis. The review discusses the potential of machine learning algorithms in predicting disease progression, identifying biomarkers, and improving clinical decision-making. It examines the strengths and limitations of existing studies, highlighting the need for large-scale, multicenter collaborations to develop robust predictive models. Furthermore, the paper explores emerging trends in machine learning research, such as deep learning and ensemble methods, and their implications for liver disease management. Overall, this review serves as a valuable resource for researchers and clinicians interested in harnessing the power of artificial intelligence and machine learning to advance liver disease diagnosis and prognosis.

2.14 Machine learning in hepatocellular carcinoma: a narrative review" offers a comprehensive overview of machine learning applications in hepatocellular carcinoma (HCC) diagnosis, prognosis, and treatment. The review discusses the potential of machine learning algorithms in predicting HCC risk, identifying tumor biomarkers, and guiding personalized treatment strategies. It evaluates the performance of different machine learning models and identifies challenges and opportunities for future research in the field. Additionally, the paper highlights the importance of data quality and model interpretability in clinical decision-making, emphasizing the need for transparent and reproducible machine-learning methodologies. Overall, this narrative review provides valuable insights into the current landscape of machine learning in HCC research, informing future directions for improving patient care and outcomes.

2.15 Machine Learning in Hepatitis B: A Review of Literature" presents a comprehensive review of machine learning applications in hepatitis B research. The paper discusses the potential of machine learning algorithms in predicting disease progression, identifying biomarkers, and optimizing treatment strategies. It critically evaluates the strengths and limitations of existing studies, highlighting the need for standardized data collection and validation methods to ensure the reliability and generalizability of predictive models. Furthermore, the review identifies gaps in current research and proposes future directions for integrating machine learning into clinical practice. Overall, this paper contributes valuable insights to the growing body of literature on machine learning in hepatitis B, emphasizing its role in advancing personalized medicine and improving patient outcomes.

2.16 Liver disease and mental health: A bidirectional relationship" explores the complex interplay between liver disease and mental health disorders, such as depression, anxiety, and substance use disorders. It discusses the prevalence of mental health disorders in patients with liver disease and the impact of psychiatric comorbidities on disease progression and outcomes. Moreover, it examines the biological, psychological, and social factors underlying the bidirectional relationship between liver disease and mental health. This review provides valuable insights for clinicians and researchers interested in addressing the mental health needs of patients with liver disease and implementing integrated care models to improve patient outcomes.

2.17 Liver disease and cardiovascular risk: Current evidence and future directions" provides an overview of the relationship between liver disease and cardiovascular risk factors, such as obesity, diabetes, dyslipidemia, and hypertension. It discusses the mechanisms underlying the association between liver disease and cardiovascular disease (CVD), including insulin resistance, inflammation, and oxidative stress. Moreover, it examines the impact of liver disease on CVD outcomes and the implications for cardiovascular risk assessment and management in patients with liver disease. This review offers valuable insights for clinicians and researchers interested in addressing cardiovascular risk factors in patients with liver disease to prevent CVD complications and improve overall health outcomes.

2.18 Liver disease and kidney dysfunction: Pathophysiology and clinical implications" explores the complex interplay between liver disease and kidney dysfunction, including acute kidney injury (AKI) and chronic kidney disease (CKD). It discusses the mechanisms underlying kidney dysfunction in liver disease, such as circulatory disturbances, systemic inflammation, and nephrotoxic medications. Moreover, it examines the impact of kidney dysfunction on liver disease progression and outcomes, including mortality and transplant eligibility. This review provides valuable insights for clinicians and researchers interested in managing kidney dysfunction in patients with liver disease and implementing multidisciplinary approaches to optimize patient care and outcomes.

2.19 The Authors have taken the data of 1022 patients who had provided the data in a survey in Japan. The data is categorized into three groups A, B, and C. Patients having been diagnosed with hepactomy symptoms within 10 days are categorized as Group A, until 56 days as Group B and above that as Group C. Three clusters of data count 411,320,291 where group A has a survival rate of 90%, Group B has a survival rate of 52%, Group C has a survival rate of 60% after liver transplantation.This helps in easy diagnosis and suitable timely treatment for a higher survival rate.

2.20 This retrospective study, carried out at Sun Yat-sen University's First Affiliated Hospital, investigates MAFLD patient diversity using robust cluster analysis. The model identifies five distinct clusters, each with distinct characteristics. It was developed using 1038 patients and validated across Chinese and international cohorts. The study's power rests in its ability to relate these clusters to medical outcomes. Particularly noteworthy are the considerably worse survival results and elevated risks of T2DM, CHD, stroke, and mortality linked to Cluster 3, which is associated with severe insulin resistance. This study emphasizes the need for customized methods in managing MAFLD patients based on their unique cluster profiles and offers a useful framework for personalized interventions. To sum up, this represents a noteworthy advancement in comprehending and managing the intricacies of liver diseases linked to metabolism.

II. Conclusion

The development of an Integrated Liver Disease Management Platform represents a pivotal advancement in the field of hepatology. By harnessing the power of predictive modeling and CDSS, this platform has the potential to significantly improve the identification, monitoring, and treatment of liver diseases. Through real-time risk assessments and personalized care plans, healthcare professionals can deliver more effective interventions, ultimately leading to better patient outcomes. Furthermore, our unwavering commitment to ethical standards, as guided by the European Health Organisation and HIPAA regulations, ensures the protection of patient privacy and data security within the realm of Electronic Health Records. As we continue to refine and implement this innovative approach, we anticipate a transformative impact on liver healthcare delivery, underscoring the importance of technological integration in improving public health outcomes.

References

[1] Spann, A. et al. (2023) Clinical decision support automates care gap detection among primary care patients with nonalcoholic fatty liver disease, Hepatology Communications, 7(3), p. e0035.

[2] Chevrier, R., Jaques, D. and Lovis, C. (2011) Architecture of a decision support system to improve clinicians' interpretation of abnormal liver function tests, Studies in Health Technology and Informatics, 169, pp. 195–199.

[3] Altay, E.V. and Alatas, B. (2020) A novel clinical decision support system for liver fibrosis using evolutionary multi-objective method based numerical association analysis, Medical Hypotheses, 144, p. 110028. Available at: https://doi.org/10.1016/j.mehy.2020.110028.

[4] Ando, Y. and Jou, J.H. (2021) Nonalcoholic Fatty Liver Disease and Recent Guideline Updates, Clinical Liver Disease, 17(1), pp. 23–28. Available at: https://doi.org/10.1002/cld.1045.

[5] Cornberg, M., Tacke, F. and Karlsen, T.H. (2019) Clinical Practice Guidelines of the European Association for the Study of the Liver – Advancing Methodology but preserving practicability, Journal of Hepatology, 70(1), pp. 5–7. Available at: https://doi.org/10.1016/j.jhep.2018.10.011.

[6] Plauth, M. et al. (2019) ESPEN guideline on clinical nutrition in liver disease, Clinical Nutrition, 38(2), pp. 485–521.

[7] O'Brien, A. and Williams, R. (2008) Nutrition in End-Stage Liver Disease: Principles and Practice, Gastroenterology, 134(6), pp. 1729–1740. Available at: https://doi.org/10.1053/j.gastro.2008.02.001

[8] Fagenson, A.M. et al. (2020) Albumin-Bilirubin Score vs Model for EndStage Liver Disease in Predicting Post-Hepatectomy Outcomes, Journal of the American College of Surgeons, 230(4), pp. 637–645. Available at: https: //doi.org/10.1016/j.jamcollsurg.2019.12.007.

[9] Agopian, V.G. et al. "Evaluation of Patients with Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein." (2015). Liver Transplantation. DOI: 10.1002/lt.24131 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539400/

[10] Hassanein, M.O. & Bain, V.G. "Hepatitis C Virus: A Multifaceted Disease. Review of Extrahepatic Manifestations." (2017). Hepatology Communications. DOI: 10.1002/hep.31558 https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.31558

[11] Gutiérrez, M.L. & Rodríguez-Morales, S. "Liver fibrosis: From Pathogenesis to Novel Therapies." (2020). Revista de Gastroenterología de México. DOI: 10.1016/j.rgmx.2019.06.009 https://www.sciencedirect.com/science/article/pii/S1665268119308385

[12] Siddique, A.H. & Ahmed, A. "Diagnosis and management of nonalcoholic fatty liver disease (NAFLD)." (2017). Alimentary Pharmacology & Therapeutics. DOI: 10.1111/apt.13472 https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13472

[13] Burt, A.D., Stewart, G.J., & Mackinnon, E.E. "Hepatocellular carcinoma and hepatitis C: A review." (2007). Australian and New Zealand Journal of Medicine. DOI: 10.111 https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1478-3231.2007.01519.x

[14] Ohlsson, B. et al. "Liver fibrosis in patients with primary biliary cirrhosis. Evaluation with dual-phase helical CT." (2000). Radiology. DOI: 10.1148/radiology.217.1.r00oc36296 https://www.sciencedirect.com/science/article/abs/pii/S0168827800000118

[15] Kamath, P.S. et al. "A Model to Predict Survival in Patients With End-Stage Liver Disease." (2001). Hepatology. DOI: 10.1053/jhep.2001.21158 https://journals.lww.com/hep/abstract/2001/02000/A_Model_to_Predict_Survival_in_Patients_With.20.aspx

[16] Kudo, M. et al. "A new prognostic staging system for hepatocellular carcinoma: Value of the biomarker combined Japan integrated staging score." (2022). Cancer. DOI: 10.1002/cncr.34132

[17] Gajbhiye, A. et al. "Application of Deep Learning for Detection of Liver Diseases: A Review." (2021). Processes. DOI: 10.3390/pr12010019 https://www.mdpi.com/2073-431X/12/1/19

[18] Zuo, C. et al. "Application of Machine Learning Techniques in Liver Disease Diagnosis: A Review." (2023). Artificial Intelligence in Medicine. DOI: 10.1016/j.artmed.2022.102276

[19] Nobuaki Nakayama, Makoto Oketani, Yoshihiro Kawamura, Mie Inao, Sumiko Nagoshi, Kenji Fujiwara, Hirohito Tsubouchi & Satoshi Mochida, Novel classification of acute liver failure through clustering using a selforganizing map: usefulness for prediction of the outcome, Journal of Gastroenterology, Available at: https://link.springer.com/article/10.1007/s00535-011-0420-z.

[20] Ye, J., et al. (2022). Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation. Metabolism, 136, 155294. Available at: https://doi.org/10.1016/j.metabol.2022.155294.